REGMF.US RemeGen Co. Ltd
- Market cap
- USD 5.62B
- P/E
- 6.7x
- P/B
- 4.22x
- ROE
- 78.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is REGMF.US undervalued?
Graham numberREGMF.US trades 11.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
RemeGen Co. Ltd fundamental analysis
No fundamental analysis for RemeGen Co. Ltd yet.
RemeGen Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About RemeGen Co. Ltd
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, ur…
Full company profileRemeGen Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
RemeGen Co. Ltd annual financial statements
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 11.3M | 390K | -70.4K | 1.42B | 768M | 1.08B | 1.71B | 3.17B | 8.98B |
| Gross Profit | 2.39M | -6.18M | -11.3M | 1.36B | 498M | 823M | 1.37B | 2.55B | 8.38B |
| Operating Income | -243M | -421M | -637M | 163M | -1.05B | -1.50B | -1.37B | 127M | 5.88B |
| EBITDA | -223M | -383M | -591M | 402M | -806M | -1.25B | -1.10B | 439M | 5.98B |
| Net Income | -270M | -430M | -698M | 276M | -999M | -1.51B | -1.47B | 690M | 7.00B |
| EPS | -0.56 | -0.90 | -1.71 | 0.57 | -1.88 | -2.80 | -2.73 | 1.26 | 12 |
| Balance Sheet | |||||||||
| Total Assets | 531M | 689M | 4.12B | 4.16B | 6.02B | 5.53B | 5.50B | 7.25B | 10.5B |
| Total Liabilities | 1.03B | 921M | 523M | 713M | 1.04B | 2.09B | 3.51B | 3.55B | 1.65B |
| Shareholders' Equity | -498M | -232M | 3.59B | 3.45B | 4.98B | 3.44B | 1.99B | 3.61B | 8.89B |
| Cash & Short-term Investments | 6.03M | 37.5M | 2.77B | 1.76B | 2.07B | 709M | 760M | 2.42B | 5.52B |
| Total Debt | 863M | 653M | 198M | 103M | 165M | 1.26B | 2.67B | 2.20B | 292M |
| Cash Flow | |||||||||
| Operating Cash Flow | -128M | -283M | -660M | 264M | -1.26B | -1.50B | -1.18B | 54.8M | 5.50B |
| Capital Expenditure | 83.7M | 65.2M | 481M | 617M | 758M | 853M | 265M | 195M | 145M |
| Free Cash Flow | -212M | -348M | -1.14B | -354M | -2.02B | -2.35B | -1.44B | -140M | 5.35B |
| Ratios | |||||||||
| ROE | - | - | -19.4% | 8.0% | -20.1% | -44.0% | -73.9% | 19.1% | 78.8% |
| ROA | -50.8% | -62.4% | -16.9% | 6.6% | -16.6% | -27.3% | -26.7% | 9.5% | 66.4% |
| Net Profit Margin | -2,384.5% | -110,271.4% | - | 19.4% | -130.1% | -140.4% | -85.9% | 21.8% | 78.0% |
| Debt to Equity | - | - | 0.05x | 0.03x | 0.03x | 0.37x | 1.34x | 0.61x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
RemeGen Co. Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | CNY 69.8M | 0.13 | - |
| 2023 | USD 15.4M | 0.03 | - |
| 2022 | USD 12.5M | 0.02 | - |
| 2021 | USD 70.7M | 0.15 | 25.6% |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns RemeGen Co. Ltd
- Insiders 10.65%
- Institutions 31.97%
- Public & others 57.39%
- Shares outstanding 209M
- Free float 347M
RemeGen Co. Ltd company profile
- Company name
- RemeGen Co. Ltd
- Ticker
- REGMF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,048
- Fiscal year end
- December
- Address
- 58 Middle Beijing Road, Yantai, China
- Phone
- 86 53 5611 3511
- Website
- remegen.com
About RemeGen Co. Ltd
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
RemeGen Co. Ltd management
10- Mr. Weidong WangCo-Founder & Executive Chairman · born 1959
- Dr. Jianmin FangCo-Founder, CEO, GM, Member of Scientific Advisory Board & Executive Director · born 1962
- Mr. Shaojing TongCFO & Company Secretary · born 1971
- Mr. Qingkai WenExecutive Director & Board Secretary · born 1966
- Mr. Kaisheng HuangChief Operating Officer
- Jian Liang WeiAccounting Supervisor
- Dr. Marie ZhuChief Technical Officer
- Dr. Xiaoming Yang Ph.D.Chief Manufacturing Officer · born 1964
- Dr. Ming Shi M.D., Ph.D.Chief Medical Officer · born 1967
- Ms. Yi FangExecutive Director